Early Tx Response Predicts 2-Year AS Outcomes
Improvement in first 3 months on secukinumab tied to better long-term response
medpagetoday.com
Secukinumab Reduces Fatigue in Patients With Ankylosing Spondylitis
By Jill Stein…
dgnews.docguide.com
Secukinumab Safety in AS Holds Up at 3 Years
Consistent with previous reports in ankylosing spondylitis, psoriasis, and psoriatic arthritis
medpagetoday.com